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Summary
Objective: To compare the probability of target attainment (PTA) for macrolides and ketolides
against penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae in both
serum and epithelial lining fluid (ELF) of patients with community-acquired pneumonia (CAP).
Methods: Monte Carlo simulations were used to assess the attainment of the bacterial eradica-
tion-linked pharmacodynamic index of the free drug area under the concentration—time curve
over 24 hours to minimum inhibitory concentration ( fAUC0—24/MIC90) by azithromycin, clari-
thromycin, and telithromycin, at therapeutic doses, against penicillin-susceptible, intermediate,
and resistant S. pneumoniae.
Results: In serum, azithromycin and clarithromycin were found to have a probability of
attaining the recommended fAUC0—24/MIC90 ratio of 30 in 50.2% and 74.6%, respectively, of
CAP patients with penicillin-intermediate strains, and a probability of 36.9% and 60.7%,
respectively, in cases of penicillin-resistant strains. Telithromycin maintained a probability
of reaching the fAUC0—24/MIC90 ratio of 30 in serum and ELF in 89.1% of CAP patients, regardless
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of the penicillin resistance of the strain.
Conclusions: Clarithromycin results in a higher PTA than azithromycin in the treatment of
penicillin-susceptible S. pneumoniae, but both of these agents exhibit a decreasing efficacy as
S. pneumoniae penicillin resistance increases. When compared to clarithromycin and azithromy-
cin, telithromycin maintains higher PTA in CAP patients with penicillin-resistant strains of S.
pneumoniae.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is currently a leading causative
organism of a wide range of community-acquired bacterial
infections, including pneumonia, otitis media, sinusitis, bac-
teremia, and meningitis.1,2 The morbidity and mortality
associated with S. pneumoniae infections continues to place
a heavy socioeconomic burden on the world community.3
Many different serotypes of S. pneumoniae are capable of
causing infection and all of them were at one time suscep-
tible to penicillin. Resistance of S. pneumoniae to penicillin
first began to develop in the 1960s and has been increasing
rapidly among isolates in the last two decades.4,5 Penicillin
resistance rates especially increased throughout the 1990s.
Penicillin-intermediate strains of S. pneumoniae increased
from 3.8% in 1989 to 27.8% in 1997,6,7 while penicillin-resis-
tant strains of S. pneumoniae increased from 2.6% in 1992 to
21.5% in 2000.8,9
Studies have shown that S. pneumoniae isolates resistant
to penicillin are also resistant to macrolide antibiotics.10
Azithromycin and clarithromycin exhibited a MIC90 (minimum
inhibitory concentration required to inhibit the growth of 90%
of isolates) of >64 mg/ml against penicillin-resistant strains,
while in cases of penicillin-susceptible strains the MIC90s
were 1 mg/ml and 0.25 mg/ml, respectively.10 The growing
resistance of S. pneumoniae to penicillins and macrolides has
led to the development of a new class of antibiotics called
the ketolides. Telithromycin was the first approved antibiotic
in this class. It shows good activity against penicillin-resistant
strains of S. pneumoniae with a MIC90 <0.25 mg/ml and has a
low probability of inducing macrolide-type resistance.10
Pharmacodynamic studies indicate that the ratio of the
area under the concentration—time curve of the free drug
over 24 hours to the MIC90 ( fAUC0—24/MIC90) correlates best
with the efficacy of azithromycin and telithromycin ther-
apy.11—13 With reference to clarithromycin, studies have
reported using fAUC0—24/MIC90, percent time above the
MIC (%T > MIC), or the ratio of peak serum concentration
of the antimicrobial agent to the MIC of the agent (Cmax/MIC)
for predicting therapeutic efficacy.14—17 In 2002, and after an
extensive pharmacodynamic study, Tessier et al. suggested
that fAUC0—24/MIC90 is the best parameter for predicting
clarithromycin efficacy since it incorporates both duration
and intensity of exposure.17 A target range of 25—35 for the
fAUC0—24/MIC90 ratio was shown to be required for azithro-
mycin and clarithromycin in order to achieve bacterial era-
dication and a positive clinical outcome in patients with S.
pneumoniae-associated community-acquired pneumonia
(CAP).18 For telithromycin, Lodise et al. indicated that an
fAUC0—24/MIC90 ratio of 3.375 is adequate in predicting
bacterial eradication in S. pneumoniae infections.19 Thisdifference is suggested to be due to the ability of telithro-
mycin to better penetrate and increase concentration at the
infection site or differences in protein binding. However,
when pharmacokinetic modeling was used in the same study
to better account for telithromycin drug penetration, a
target fAUC0—24/MIC90 ratio of about 27 for bacterial eradi-
cation was estimated.19
With the continuing rise in penicillin resistance among S.
pneumoniae isolates, it is important to evaluate the ability of
macrolides and ketolides to achieve a favorable clinical
outcome against resistant strains in S. pneumoniae-related
infections. The purpose of this study was to compare the
pharmacodynamic target attainment potential of azithromy-
cin, clarithromycin, and telithromycin at the standard doses
to achieve fAUC0—24/MIC90 of 30, 40, and 100 in both
serum and the epithelial lining fluid (ELF) against penicillin-
susceptible (PS), penicillin-intermediate (PI), and penicillin-
resistant (PR) S. pneumoniae in CAP patients.
Materials and methods
Pharmacokinetic simulations
Published pharmacokinetic parameters of azithromycin,
clarithromycin, and telithromycin were used to simulate
the distribution of the free drug exposure measures
( fAUC0—24) in both serum and ELF when given to CAP patients
at doses of 500/250 mg once daily, 500 mg twice daily, and
800 mg once daily, respectively.20
Pharmacodynamic simulations
Susceptibility data of azithromycin, clarithromycin, and teli-
thromycin against PS, PI, and PR S. pneumoniae were
obtained from the Canadian Respiratory Organism Suscept-
ibility Study (CROSS).21,22 CROSS is a longitudinal national
surveillance program that studies the incidence of antibiotic
resistance in respiratory pathogens across all regions of
Canada. The outcome linked parameter, fAUC0—24/MIC90,
of the tested drugs was estimated by dividing the simulated
fAUC0—24 values by the MIC90 values obtained from the CROSS
study.
Monte Carlo simulation analysis
A Monte Carlo simulation of a 10 000 patient population was
performed to determine the percentage of patients achiev-
ing an fAUC0—24/MIC90 ratio of 30, 40, and 100 in both
serum and ELF after the previously described azithromycin,
clarithromycin, and telithromycin dosing regimens and eval-
uated against PS, PI, and PR S. pneumoniae. Monte Carlo
Table 1 Probability of target attainment (PTA, %) of fAUC0—24/MIC90 ratios for azithromycin, clarithromycin, and telithromycin at
standard therapeutic doses in serum and ELF of CAP patients with penicillin-susceptible (PS), penicillin-intermediate (PI), and
penicillin-resistant (PR) Streptococcus pneumoniae.
PTA in serum (%) PTA in ELF (%)
PS PI PR PS PI PR
Drug/dose 30 40 100 30 40 100 30 40 100 30 40 100 30 40 100 30 40 100
Azithromycin
500/250 mg,
once daily
81.4 81.3 69.9 50.2 40.6 0.0 36.9 26.8 0.0 82.3 81.9 80 53.0 52.4 49.4 38.7 38.2 37.2
Clarithromycin
500 mg,
twice daily
91.3 89.2 84.7 74.6 69.3 61.2 60.7 56.0 46.8 99.9 99.9 93.9 83.0 83.0 80.3 72.3 72.3 70.5
Telithromycin
800 mg,
once daily
99.0 98.6 96.0 95.4 94.2 87.9 89.1 84.2 73.9 100 100 99.8 99.8 99.8 99.1 99.8 99.8 98.8
fAUC0—24, free drug area under the concentration—time curve over 24 hours; MIC90, minimum inhibitory concentration required to inhibit
the growth of 90% of isolates; ELF, epithelial lining fluid; CAP, community-acquired pneumonia.
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2000 program (Decisioneering UK Ltd, London, UK).23—25
Using Monte Carlo simulation allowed for complete account-
ability of the MIC distribution of S. pneumoniae isolates as
well as the variability in drug exposure among CAP patients.
Results
The probability of attainment of the fAUC0—24/MIC90 target
ratios for azithromycin, clarithromycin, and telithromycin
against PS, PI, and PR S. pneumoniae are shown in Table 1 and
Figures 1 and 2.
Penicillin-susceptible S. pneumoniae
For azithromycin 500/250 mg once daily, the probability of
achieving an fAUC0—24/MIC90 ratio of 30 in serum was 81.4%
and in ELF was 82.3%, but it decreased to be 69.9% in serum
and 80% in ELF when the target value was set to 100. WithFigure 1 Probability of attainment of the fAUC0—24/MIC90 target o
serum of community-acquired pneumonia patients with penicillin
resistant (PR) Streptococcus pneumoniae.reference to clarithromycin 500 mg twice daily, the prob-
ability of achieving a target value of 30 in serum was 91.3%
and in ELF was 99.9%, and at a target value of 100, it was
84.7% in serum and 93.9% in ELF. Telithromycin use of 800 mg
once daily had a probability of achieving an fAUC0—24/MIC90
of 30 in 99% and 100 in 96% in serum, and an fAUC0—24/MIC90
of 30 in 100% and 100 in 99.8% in ELF.
Penicillin-intermediate S. pneumoniae
Azithromycin 500/250 mg once daily had a probability of
50.2% and 0.0% in serum and 53.0% and 49.4% in ELF for
achieving the target values of 30 and 100, respectively.
Clarithromycin use at 500 mg twice daily yielded a probabil-
ity of 74.6% and 61.2% in serum and 83.0% and 80.3% in ELF at
the target values of 30 and 100, respectively. Telithromycin
use of 800 mg once daily had a probability of 95.4% and 87.9%
in serum and 99.8% and 99.1% in ELF at fAUC0—24/MIC90 of 30
and 100, respectively.f 30 for azithromycin, clarithromycin, and telithromycin in the
-susceptible (PS), penicillin-intermediate (PI), and penicillin-
Figure 2 Probability of attainment of the fAUC0—24/MIC90 target of 30 for azithromycin, clarithromycin, and telithromycin in the
epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible (PS), penicillin-intermediate (PI), and
penicillin-resistant (PR) Streptococcus pneumoniae.
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Use of azithromycin 500/250 mg once daily in the Monte
Carlo simulation had a probability of 36.9% and 0.0% in
serum and 38.7% and 37.2% in ELF for achieving fAUC0—24/
MIC90 of 30 and 100, respectively. Clarithromycin use of
500 mg twice daily yielded a probability of 60.7% and 46.8%
in serum and 72.3% and 70.5% in ELF at the target values of
30 and 100, respectively. Telithromycin use of 800 mg once
daily had a probability of 89.1% and 73.9% in serum and
99.8% and 98.8% in ELF at fAUC0—24/MIC90 of 30 and 100,
respectively.
Discussion
Studies have shown that bacterial eradication can be pre-
dicted by the relationship between the pathogen’s MIC
and drug exposure.26,27 Pharmacodynamic studies indicate
that the fAUC0—24/MIC90 ratio correlates best with pre-
dicting efficacy of azithromycin, clarithromycin, and teli-
thromycin therapy.11—13,17 Pharmacodynamic study data
for azithromycin and clarithromycin has shown an
fAUC0—24/MIC90 ratio of 25—35 to be necessary to predict
bacterial eradication and a positive clinical outcome in
patients with S. pneumoniae-associated CAP.18 For teli-
thromycin, an fAUC0—24/MIC90 ratio of 27 was found
to be adequate in predicting bacterial eradication in S.
pneumoniae infections.19
When simulating the pharmacodynamics of these agents in
serum and ELF of CAP patients with PI S. pneumoniae, our
data showed variability in the probability of target attain-
ment (PTA) between these agents (Table 1). The Monte Carlo
simulation data show that azithromycin can only reach the
suggested fAUC0—24/MIC90 ratio of 30 in 50.2% of patients.
Using clarithromycin increases the probability of attaining
the fAUC0—24/MIC90 ratio of 30 to 74.6% of patients. Simulat-
ing administration of the ketolide telithromycin increases the
probability of attaining the fAUC0—24/MIC90 ratio of 30
against PI S. pneumoniae to 95.4%.
In the pharmacodynamic simulations of these agents in
serum and ELF of CAP patients with PR S. pneumoniae, ourdata indicate an even greater difference in the PTA than with
the PI strains (Table 1). Azithromycin Monte Carlo simulation
data predict only a 36.9% chance of achieving the fAUC0—24/
MIC90 ratio of 30 to produce bacterial eradication, and
clarithromycin treatment only has a probability of target
attainment of 60.7% in the serum of CAP patients. In contrast,
according to our data, the newer ketolide telithromycin
maintains a high probability of reaching the fAUC0—24/
MIC90 ratio of 30 in serum and ELF at 89.1% of CAP patients
with PR strains.
Based on these findings we conclude that all three of these
agents are adequate in producing a high probability of
achieving a favorable clinical outcome at normal therapeutic
doses in serum and ELF of CAP patients with PS strains of S.
pneumoniae. Clarithromycin results in better pharmacody-
namic target attainment than azithromycin, but both of
these agents exhibit a decreased probability of achieving
the fAUC0—24/MIC90 ratio of 30, which is predictive of bac-
terial eradication, as S. pneumoniae penicillin resistance
increases.
The lower pharmacodynamic target attainment poten-
tial of azithromycin can lead to the selection of resistant
mutants resulting in higher potential for the development
of bacterial resistance. These findings are consistent with
other clinical findings that showed higher probability for
the selection of macrolide resistance when azithromycin
was used vs. clarithromycin or erythromycin and hence,
patients treated with azithromycin were more likely to
have macrolide-resistant organisms.28 Telithromycin
800 mg once daily maintains a high probability of pharma-
codynamic target attainment against PR strains of S. pneu-
moniae, and thus from a bacteriological eradication
perspective, other ketolides such as cethromycin need to
be evaluated for potential target attainment against PR
strains of S. pneumoniae. This study only evaluated the
efficacy of azithromycin, clarithromycin, and telithromycin
against S. pneumoniae possessing different levels of peni-
cillin resistance. Further studies are required to evaluate
the efficacy against S. pneumoniae strains that are resistant
to other drug classes.
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